Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
January 2025
in “
Annals of Dermatology
”
Research cited in this study
7 / 7 results
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Predominant Expression of Interleukin-17 in Chronic Alopecia Areata Compared to IFN-γ in Pathogenic Th17 Cells, Tissue-Resident Memory T Cells and Natural Killer Cells
IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Local Heroes or Villains: Tissue-Resident Memory T Cells in Human Health and Disease
Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
Related Research
1 / 1 results
research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child
A child with rough nails also had hair loss and allergies.